Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Trevi Therapeutics stock | $2.86

Own Trevi Therapeutics stock in just a few minutes.

Fact checked

Trevi Therapeutics, Inc is a biotechnology business based in the US. Trevi Therapeutics shares (TRVI) are listed on the NASDAQ and all prices are listed in US Dollars. Trevi Therapeutics employs 22 staff and has a market cap (total outstanding shares value) of USD$56.6 million.

How to buy shares in Trevi Therapeutics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Trevi Therapeutics. Find the stock by name or ticker symbol: TRVI. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Trevi Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$2.86, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Trevi Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Trevi Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Trevi Therapeutics share price

Use our graph to track the performance of TRVI stocks over time.

Trevi Therapeutics shares at a glance

Information last updated 2020-12-01.
Latest market closeUSD$2.86
52-week rangeUSD$1.33 - USD$8.49
50-day moving average USD$3.335
200-day moving average USD$4.2092
Wall St. target priceUSD$11
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-9.144

Buy Trevi Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
Stocks, Forex
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, ETFs
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
$0 for US stocks
Stocks, Options, ETFs
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Trevi Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Trevi Therapeutics price performance over time

Historical closes compared with the close of $2.86 from 2020-12-09

1 week (2021-01-12) N/A
1 month (2020-12-23) 7.12%
3 months (2020-10-19) N/A
6 months (2020-07-19) N/A
1 year (2020-01-19) N/A
2 years (2019-01-19) N/A
3 years (2018-01-19) N/A
5 years (2016-01-19) N/A

Trevi Therapeutics financials

Gross profit TTM USD$0
Return on assets TTM -30.83%
Return on equity TTM -61.81%
Profit margin 0%
Book value $1.944
Market capitalisation USD$56.6 million

TTM: trailing 12 months

Shorting Trevi Therapeutics shares

There are currently 44,988 Trevi Therapeutics shares held short by investors – that's known as Trevi Therapeutics's "short interest". This figure is 5.9% down from 47,788 last month.

There are a few different ways that this level of interest in shorting Trevi Therapeutics shares can be evaluated.

Trevi Therapeutics's "short interest ratio" (SIR)

Trevi Therapeutics's "short interest ratio" (SIR) is the quantity of Trevi Therapeutics shares currently shorted divided by the average quantity of Trevi Therapeutics shares traded daily (recently around 18287.804878049). Trevi Therapeutics's SIR currently stands at 2.46. In other words for every 100,000 Trevi Therapeutics shares traded daily on the market, roughly 2460 shares are currently held short.

However Trevi Therapeutics's short interest can also be evaluated against the total number of Trevi Therapeutics shares, or, against the total number of tradable Trevi Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Trevi Therapeutics's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Trevi Therapeutics shares in existence, roughly 0 shares are currently held short) or 0.0081% of the tradable shares (for every 100,000 tradable Trevi Therapeutics shares, roughly 8 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Trevi Therapeutics.

Find out more about how you can short Trevi Therapeutics stock.

Trevi Therapeutics share dividends

We're not expecting Trevi Therapeutics to pay a dividend over the next 12 months.

Trevi Therapeutics overview

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. Its Haduvio (nalbuphine ER), which is in Phase IIb/III clinical trial is an oral extended release formulation of nalbuphine that is used for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease, as well as to treat chronic kidney disease-associated with pruritus. The company was founded in 2011 and is headquartered in New Haven, Connecticut.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site